# Clinical Trials Data KIT - Document 58

# Staging Candidiasis in ICU Patients

## Clinical Trial: https://clinicaltrials.gov/study/NCT01322698

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Polynuclear neutrophils \\> 500/mm\\^3\n\* Hospitalized for \\> 48 hours in participating ICUs\n\nExclusion Criteria:\n\n\* Patients discharged from ICU in \\< 48h\n\* Patient diagnosed with invasive candidosis before entry to ICU\n\* Patient is taking an anti-fungal treatment\n\* polynuclear neutrophils \\< 500/mm\\^3\n\* patient transferred to another ICU\n\* patient included in the Abmidex protocole",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "The target population includes patients in ICUs at the N\u00eemes and Montpellier University hospitals. This is a population of non-neutropenic patients (polynuclear neutrophils \\> 500/mm3) at risk of developing invasive candidiasis.",

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
The provided information doesn't mention KIT gene mutations as either an inclusion or exclusion criterion. Therefore, having a KIT gene mutation \*doesn't automatically disqualify\* a patient. They would need to meet all other inclusion criteria and not meet any exclusion criteria to be eligible.